MMWR Booster #2: Epidemiologic and Clinical Features of Mpox in Transgender and Gender-Diverse Adults — United States, May–November 2022
Top 5 Takeaways:
Mpox Prevalence in Transgender and Gender-Diverse Adults: During May 17–November 4, 2022, there were 466 reported mpox cases in transgender and gender-diverse adults in the U.S., constituting 1.7% of adult cases, with most cases in transgender women (43.1%) or gender-diverse persons (42.1%).
Sexual Contact Trends: Among 374 cases with available data, 276 (73.8%) reported sexual or close intimate contact with a cisgender male partner within three weeks before symptom onset.
Racial and Ethnic Distribution: Among transgender and gender-diverse adults with mpox, 37.0% were Hispanic, 28.1% non-Hispanic White, and 27.6% non-Hispanic Black, mirroring the distribution in cisgender persons.
Symptoms and HIV Status: Common symptoms included rash, malaise, and fever. Among 166 patients with available HIV status data, 47.6% were HIV positive.
Hospitalization Rates: Of the transgender and gender-diverse adults with mpox, 6.9% were hospitalized, which is similar to the rate in cisgender adults. Link: BroadlyEpi.com
